MHRA

#CAR-T #FDA #MHRA #Monoclonal antibodies #NMPA #Oncology #Regulatory

New DDW Highlights podcast: 15 January 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week has seen a number of significant discoveries by researchers in academic institutions,… Read More

#News

#CAR-T #FDA #MHRA #Monoclonal antibodies #NMPA #Oncology #Regulatory

This week in drug discovery (8-12 January) 

News round-up for 8-12 January by DDW Digital Content Editor Diana Spencer. This week has seen a number of significant discoveries by researchers in academic institutions, in some cases in partnership with industry, emphasising the important role universities play in early-stage drug discovery. Perhaps most importantly,… Read More

#News

#CAR-T #FDA #MHRA #Monoclonal antibodies #NMPA #Oncology #Regulatory

New DDW Highlights podcast for 8 January 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The start of 2024 has seen quite a bit of regulatory activity, with the… Read More

#News

#CAR-T #FDA #MHRA #Monoclonal antibodies #NMPA #Oncology #Regulatory

This week in drug discovery (1-5 January) 

News round-up for 1-5 January by DDW Digital Content Editor Diana Spencer. The start of 2024 has seen quite a bit of regulatory activity, with the UK MHRA’s launch of a new procedure for assessing drugs, along with significant regulatory approvals for therapeutics for cytomegalovirus, melanoma,… Read More

#News

#ABPI #Marketing approval authorisation #MHRA #Regulatory #UK

New UK authorisation policy draws on international drug approvals

The UK Medicines and Healthcare products Regulatory Agency’s (MHRA) new International Recognition procedure (IRP) will allow it to draw on the expertise of regulators in other countries when authorising medicines. The MHRA will retain ultimate authority to accept or reject applications submitted under the IRP, but it is hoped that… Read More

#News #Regulatory

Monoclonal antibody
#Bristol Myers Squibb #Melanoma #MHRA #Monoclonal antibodies #Project Orbis

Nivolumab-relatlimab combination for melanoma approved in UK

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Bristol Myers Squibb’s advanced melanoma drug Opdualag (nivolumab-relatlimab) for patients from the age of 12. Opdualag was authorised through Project Orbis, a global partnership between the MHRA, the Therapeutics Goods Administration in Australia, Health Canada, the Health Sciences Authority… Read More

#News #Regulatory

Woman suffering from hot flushes
#Astellas Pharma #European Commission #Menopause #MHRA #Women's health

Novel hot flushes treatment approved in UK and EU

Astellas’ Veoza (fezolinetant) will soon be available to some women in the UK suffering from vasomotor symptoms (VMS) associated with menopause following approval by the Medicines and Healthcare Regulatory Agency (MHRA). Despite VMS, or hot flushes, being a common symptom of menopause, until now, hormone replacement therapy (HRT) was the… Read More

#Editor's Choice #News #Regulatory

CRISPR gene editing
#CRISPR #CRISPR Therapeutics #Gene therapy #MHRA #Sickle cell disorder (SCD) #Vertex

Great Britain first to approve CRISPR-based gene therapy

The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised the world’s first gene therapy for sickle-cell disease (SCD) and transfusion-dependent β-thalassemia (TDT). Casgevy (exagamglogene autotemcel, or exa-cel) is the first medicine to be licensed that uses gene editing tool CRISPR, for which its inventors were awarded the Nobel Prize… Read More

#News #Regulatory #Trending News

#Eli Lilly #FDA #MHRA #Obesity #Regulatory #Weight loss

Tirzepatide approved for weight management in US and UK

The US Food and Drug Administration has approved Zepbound (tirzepatide) injection for chronic weight management alongside a reduced calorie diet and increased physical activity. It is approved in adults with obesity (body mass index of 30 kilograms per square meter (kg/m2) or greater) or overweight (body mass index of 27kg/m2… Read More

#News #Regulatory #Trending News

Medical professional examining mammogram
#Breast cancer #Drug repurposing #Hormone therapy #MHRA #Oncology #UK

UK women to benefit from drug to prevent breast cancer

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorised a new indication for anastrozole, to prevent breast cancer in post-menopausal women at moderate or high risk of developing the disease. The hormone treatment was already authorised for use in the treatment of breast cancer… Read More

#News #Trending News

Non-small cell lung cancer
#Lung cancer #MHRA #Mirati Therapeutics #Non-small cell lung cancer (NSCLC) #Oncology #UK

MHRA approves drug for lung cancer with limited therapy options

The UK regulator has approved a new treatment for non-small cell lung cancer (NSCLC) in adults that has a mutation and produces a rare protein called KRAS G12C. The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Krazati (adagrasib) to treat patients whose disease is advanced or has spread… Read More

#News #Regulatory

Hematopoietic cells
#Cancer research #Clinical trial #Gene therapy #MHRA #Paediatrics #Phase I trial #Stem cells #UK

First gene therapy trial for Hunter syndrome opens in Manchester, UK

UK regulatory authorities have approved the first trial of a gene therapy for young children with Hunter syndrome. The UK Medicines and Healthcare Products Regulatory Agency (MHRA), Research Ethics Committee (REC), and Health Research Authority (HRA) have all approved the clinical trial application that was submitted by The University of… Read More

#Editor's Choice #News #Regulatory

Blood cancer
#Bispecific Antibodies #Cancer research #Haematology #MHRA #Oncology #UK

New UK therapy option for hard-to-treat lymphoma

The MHRA has granted conditional marketing authorisation for Tepkinly (epcoritamab) as a bispecific treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The conditional marketing authorisation for Great Britain is based on the single-arm Phase I/II EPCORE NHL-1 trial… Read More

#News #Regulatory

MHRA
#Clinical Trial Authorisation #Clinical trial design #Clinical trials #MHRA #Phase III trial #UK

UK regulator cuts late-stage clinical trial approval time to two weeks

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has revealed plans to reduce the time taken to approve the lowest-risk clinical trials by more than 50%. According to the plans, initial applications for the lowest-risk Phase III and IV trials will be processed by the MHRA within 14 days… Read More

#News #Regulatory

CAR-T therapy
#Cancer research #CAR-T #Leucid Bio #MHRA #Oncology #Solid tumours

CAR-T therapy targets over 80% of human tumours

Leucid Bio has been granted clinical trial authorisation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I/II clinical trial evaluating autologous NKG2D-targeted CAR-T cell therapy, LEU011, in patients with relapsed or refractory solid tumours. The open-label, single patient cohort ascending… Read More

#Cancer Research #Editor's Choice #News

Close up of vaccine syringe
#BioNTech #Comirnaty #Covid-19 #Covid-19 vaccine #MHRA #Omicron #Pfizer

UK regulator approves Pfizer/BioNTech’s adapted Covid-19 vaccine

Approval has been granted by the Medicines and Healthcare products Regulatory Agency (MHRA) for an adapted Pfizer/BioNTech Covid-19 vaccine that targets the Omicron XBB 1.5 subvariant. The new version of Comirnaty was found to meet the UK regulator’s standards of safety, quality and effectiveness and has… Read More

#News #Trending News